Protocol Optimization in MRI: High-Relaxivity Contrast and Contrast Boosting

RSNA® 2026
AT THE CENTER OF CARE



Emanuel Kanal, MD, FACR, FISMRM, MRMD/SE, AANG
Chief, Division of Emergency Radiology
Director, Magnetic Resonance Services
Professor of Radiology and Neuroradiology
University of Pittsburgh Medical Center
University of Pittsburgh School of Medicine
Pittsburgh, PA



Ali Pirasteh, MD
Chief, MRI; Director, PET/MRI
Department of Radiology
School of Medicine and Public Health
University of Wisconsin-Madison
Madison, Wisconsin



Bronwyn Hamilton, MD
Professor of Radiology
Courtesy appointment, Otolaryngology, Head & Neck Surgery
Oregon Health & Science University
President, Western Neuroradiological Society
Portland, Oregon

Agenda

9:30am - Arrival
9:30am - Benefits You Can Only Get from a High Relaxivity MR Contrast Agent - *Emanuel Kanal, MD, FACR, FISMRM, MRMD/SE, AANG*
9:50am - Dose and Relaxivity: How Do I Pick My Contrast Agent? - *Ali Pirasteh, MD*
10:05am - Turning up the Gain: Contrast-Boosting Software in Brain Tumor Imaging - *Bronwyn Hamilton, MD*
10:20am - Q&A Discussion - *All Faculty*
10:30am - End of Session

Monday, November 30, 2026
9:30am – 10:30am
McCormick Place | Room: S105A

Register Here Now

**CME credit must be claimed separately through Northwest Imaging Forums. Attendance is open to RSNA Annual Meeting Registrants.*

Statement of Need / Program Description: The evolving landscape of MRI contrast agents and emerging contrast-enhancement technologies presents new opportunities to optimize imaging protocols, improve diagnostic performance, and support informed clinical decision-making. With the availability of high-relaxivity gadolinium-based contrast agents, radiologists must understand how differences in relaxivity, dosing, and agent characteristics influence image quality and contrast enhancement. Additionally, advances in contrast-boosting software offer new approaches to enhancing lesion conspicuity, particularly in neuroimaging. This educational session will address these developments, providing practical insights into contrast agent selection, dose optimization, and emerging technologies to support effective and individualized MRI protocols.

Learning Objectives:

1. Understand how contrast-boosting software can add value in clinical brain tumor imaging practice
2. Describe the clinical benefits of high-relaxivity gadolinium-based contrast agents and their impact on image quality and diagnostic performance.
3. Evaluate the relationship between contrast agent relaxivity, dosing considerations, and clinical imaging requirements to inform appropriate contrast agent selection and MRI protocol optimization.

Target Audience: The content of this CME live symposium is intended for healthcare professionals including radiologists and other physicians, radiologic and imaging nurses, facility managers, researchers, and others.

Accreditation Credit Statements: This CME activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the sponsorship of Northwest Imaging Forums. NWIF is accredited by the ACCME to provide CME for physicians. NWIF designates this educational activity for 1.0 *AMA PRA Category 1 Credits*™. Physicians should only claim credit commensurate with the extent of their participation in the activity for which they attended. Nurses may claim credit for activities approved for *AMA PRA Category 1 Credits*™ in most states, for up to 50% of the nursing requirement for recertification. This course is designated for 1.0 *AMA PRA Category 1 Credits*™.

Faculty and Planner Disclosures: As an accredited provider of continuing medical education, Northwest Imaging Forums, Inc. (NWIF) ensures balance, independence, objectivity, and scientific rigor in all its educational activities. In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, all faculty and planners are required to disclose all financial relationships with ineligible companies within the last 24 months. All relevant financial relationships have been mitigated by NWIF to ensure the integrity of the CME activity. The planner has nothing to disclose.

Presented by Northwest Imaging Forums, Inc.
Supported with an unrestricted educational grant provided by Bracco Diagnostics Inc.

NW IMAGING FORUMS, INC.